Description |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Atezolizumab 1200mg/20ml |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Oncovanz |
Bleomycin 15U |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Martin Dow |
Ondansetron 8mg/4ml |
Product Type |
Product Size |
Tablets |
30'S |
Product Company |
Beacon Pharmaceuticals |
Sorafenib 200mg |
Product Type |
Product Size |
Product Company |
Injection |
1'S |
Searle Pharma |
|
Product Type |
Product Size |
Product Company |
Injection |
1'S |
Pharmasol |
|
Content | "
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and alveolar soft part sarcoma. | Bleomycin has approval for adult use in treating squamous cell cancer of head and neck regions, Hodgkin's lymphoma, testicular carcinoma. It is also used as a sclerosing agent for malignant pleural effusions. | Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is in a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
| Rituximab, an anti CD20 monoclonal antibody, is used in the management of lymphoproliferative and autoimmune conditions. | Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. So, it stops the growth of the cancer. |
Reviews
There are no reviews yet.